N
Neuroglee Therapeutics
Discovers, develops, and commercializes software as medical treatment for patients with neurodegenerative diseases
About Neuroglee Therapeutics
Neuroglee is a healthcare startup that operates in the digital health sector, specifically focusing on cognitive care. The company has developed a platform that measures cognitive functioning and well-being of patients throughout their care journey. The platform is designed to serve patients with cognitive impairments, such as those diagnosed with mild cognitive impairment (MCI), and their families.
Read full description
Neuroglee's business model revolves around providing personalized care plans to help patients form healthy habits and develop practical skills to protect brain health and maintain independence. The company's clinical team provides continuous support, recommends personalized changes to the patient's program, and identifies health concerns early. This integrated approach bridges the gap between the patient's local healthcare team and their home, ensuring optimal care.
The company's digital solutions connect patients and families throughout the care journey with support communities, resources, and exercises to manage the patient's condition. The goal is to slow neurocognitive decline and promote independence. For instance, a patient like Barbara, diagnosed with MCI, would regularly participate in Neuroglee's software-based cognitive training program. The company monitors her cognitive performance, reports improvements to her care team, and recommends educational material to help her stay on track.
Neuroglee generates revenue by partnering with healthcare providers and institutions, like the Mayo Clinic, to digitize and integrate their cognitive care programs into Neuroglee's platform. This allows healthcare providers to offer their patients a comprehensive, digital cognitive care solution.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Singapore, Singapore
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 58.2/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Disability tech, Digital Therapeutics, Tech for Biotech and Pharma, Tech for Hospitals and Clinics, Tech for Patients, Hard Tech
- Technology
- Artificial Intelligence, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Neuroglee Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2021 | $10M | $40M | Ramen Singh · EDBI · Eisai · Wendou Liu | ↗ |
| SEED✓Equity / VC | Dec 2020 | $2.3M | $9.2M | Eisai | — |
Growth signals
Latest recorded traffic for Neuroglee Therapeutics is 950 monthly website visits, down 2.1% over the last three months. Neuroglee Therapeutics's team declined 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Eisai
Series A4 investors entered at this stage
EDBI
Openspace Ventures- RSRamen Singh
- WLWendou Liu
Other known investors2 additional known investors
2050 Capital
Fernand Lendoye
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuroglee Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuroglee Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







